Hypercalcemia and huge splenomegaly presenting in an elderly patient with B-cell non-Hodgkin's lymphoma: a case report by Ghazi, Ali AM et al.
CASE REPORT Open Access
Hypercalcemia and huge splenomegaly
presenting in an elderly patient with B-cell














Introduction: Hypercalcemia is the major electrolyte abnormality in patients with malignant tumors. It can be due
to localized osteolytic hypercalcemia or elaboration of humoral substances such as parathyroid hormone-related
protein from tumoral cells. In hematological malignancies, a third mechanism of uncontrolled synthesis and
secretion of 1-25(OH)2D3 from tumoral cells or neighboring macrophages may contribute to the problem.
However, hypercalcemia is quite unusual in patients with B-cell non-Hodgkin’s lymphoma.
Case presentation: An 85-year-old Caucasian woman presented with low grade fever, anorexia, abdominal
discomfort and fullness in her left abdomen for the last six months. She was mildly anemic and complained of
fatigability. She had huge splenomegaly and was hypercalcemic. After correction of her hypercalcemia, she had a
splenectomy. Microscopic evaluation revealed a malignant lymphoma. Her immunohistochemistry was positive for
leukocyte common antigen, CD20 and parathyroid hormone-related peptide.
Conclusion: Immunopositivity for parathyroid hormone-related peptide clearly demonstrates that hypersecretion of
a parathyroid hormone-like substance from the tumor had led to hypercalcemia in this case. High serum calcium is
seen in only seven to eight percent of patients with B-cell non-Hodgkin’s lymphoma, apparently due to different
mechanisms. Evaluation of serum parathyroid hormone-related protein and 1-25(OH)2D3 can be helpful in
diagnosis and management. It should be noted that presentation with hypercalcemia has a serious impact on
prognosis and survival.
Introduction
Hypercalcemia is the major electrolyte abnormality in
patients with malignant tumors. It can be due to skeletal
invasion, known as localized osteolytic hypercalcemia or
elaboration of humoral substances such as parathyroid
hormone-related protein (PTHrP) from tumoral cells. In
hematological malignancies, a third mechanism, uncon-
trolled synthesis and secretion of 1-25(OH)2D3 from
tumoral cells or neighboring macrophages, may contri-
bute to the problem [1,2].
Hypercalcemia is common in patients with hematolo-
gical malignancies. About 30% of patients with multiple
myeloma and 60% of patients with T-cell non-Hodgkin’s
lymphoma (NHL) experience hypercalcemia due to
osteolytic mechanisms or PTHrP hypersecretion respec-
tively. By contrast, hypercalcemia is seen in only seven
to eight percent of patients with B-cell NHL [3], mostly
due to uncontrolled endogenous production of 1-25
(OH)2D3 from tumor cells. Hypercalcemia that is sec-
ondary to elaboration of PTHrP in patients with B-cell
NHL is quite unusual and, according to the best of our
knowledge, limited numbers of such patients have been
observed [3-7].
In our case report, we present the case of an 85-year-
old Iranian woman who had huge splenomegaly and
hypercalcemia. She was finally proven to have a PTHrP-
producing B-cell lymphoma of her spleen.
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An 85-year-old Iranian, Caucasian woman presented
with low grade fever, anorexia, abdominal discomfort
and fullness in her left abdomen for the last six months.
An abdominal computed tomography (CT) scan per-
formed six months previously revealed a filling defect in
her spleen, which was interpreted as a splenic cyst. No
specific treatment was done at that time.
On examination, she was mildly anemic and com-
plained of fatigability. On abdominal examination a
markedly enlarged spleen was palpated. No peripheral
lymphadenopathy was noted. Table 1 shows her labora-
tory data. Unfortunately, her PTHrP measurement was
not available to us. Her chest and mediastinal CT scan
was unremarkable except for some fibrotic changes
compatible with her age. No mediastinal lymphadenopa-
thy was seen. In her abdominal CT scan, it was noted
that her spleen was large and that it contained a definite
mass occupying about two thirds of the splenic space.
No abdominal or para-aortic lymph nodes were seen
(Figure 1).
Her serum calcium was gradually corrected by the use
of intravenous saline and furosemide over the next few
days. She did not receive any other specific treatment
for her hypercalcemia (such as calcitonin or bisphospho-
nates). On the fifth day of her admission, she underwent
a total splenectomy and a huge spleen measuring 22 ×
18 × 14 cm, weighing 1800 grams and harboring a firm
mass was extracted. Microscopic evaluation revealed a
high-grade malignant lymphoma with foci of necrosis
(Figure 2). Her immunohistochemistry was positive for
LCA, CD20, and PTHrP (Figure 3). After surgery her
serum calcium levels were 8.5-9.6 mg/dl but her low
grade fever and anorexia resumed. A bone marrow
biopsy was performed and there was no bone marrow
involvement. Based on the lack of lytic bone lesions, no
bone marrow involvement, no plasmacytosis in her bone
marrow, and the lack of gammopathy in her serum pro-
tein electrophoresis, other hematological malignancies,
Table 1 Laboratory data of the patient on admission
Patient Normal range
Hb 11.4 12-14 g/dl
WBC 8.1*10/ml 4-10.8 × 10
3/ml
Ca 13.3 8.5-10.3 mg/dl
P 3.5 2.5-4.5 mg/dl
Creatinin 1.9 0.5-1.2 mg/dl
PTH 15 15-65 pg/ml
LDH 936 <480 IU/L
25OH D3 8.6 <30 ng/ml
1-25(OH)2D3 12.7 20-70 pg/ml
24 h Urine Calcium 208 <120 mg/24 h
ESR 62 6-20 mm
Figure 1 An abdominal CT scan of the patient during the first
hospital admission.
Figure 2 PTHrP immunostaining.
Figure 3 H&E staining (hematoxylin and eosin staining).
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treated with six courses of R-CHOP. Based on her age
(85-years-old), weight (70 kg), height (1.58 m) and body
surface area (1.7 m
2), the dosage of the chemotherapy
regimen was as follows: 350 mg/m
2 of rituximab for a
total dose of 600 mg, 600 mg/m
2 of cyclophosphamide
for a total dose of 1000 mg, 40 mg/m
2 of Adriamycin
(doxorubicin) for a total dose of 70 mg, 1.4 mg/m
2 of
Oncovin (vincristine) for a total dose of 2 mg per injec-
tion and 75 mg of prednisolone daily for five days. After
the second course of chemotherapy, her general condi-
tion improved, her fever disappeared and her appetite
resumed. Five months after therapeutic courses, there
were no clinical or laboratory signs of disease. Figure 4
shows an abdominal CT scan performed one year after
surgery.
Discussion
Immunohistochemistry immunopositivity for PTHrP
clearly demonstrates that hypersecretion of the PTH-
like substance from the tumor had led to hypercalcemia
in this case. Contrary to Adult T-cell leukemia/lym-
phoma (ATLL) in which hypercalcemia is common and
almost always secondary to PTHrP hypersecretion, high
serum calcium is seen in only seven to eight percent of
patients with B-cell NHL, apparently due to different
mechanisms. Majumdar in his study on 112 patients
with B-cell NHL showed that eight patients (7.1%), six
with high grade and two with low grade disease had ele-
vated serum calcium levels [8]. Most patients had stage
3 and 4 (Stage 3: NHL is in two lymph node groups,
with/without partial involvement of an extranodal organ
or site above and below the diaphragm. Stage 4: NHL is
extensive (diffuse) in one organ or site, with/without
NHL in distant lymph nodes.) and survived between
two to 11 months after the appearance of hypercalce-
mia. No explanation about the etiology of hypercalcemia
was given in that paper.
The first study that linked elevated serum calcium to
hypersecretion of PTHrP from the tumoral cells belongs
to Wada et al [9]. In their study about a 40-year-old
man with B-cell NHL, the authors demonstrated not
only high serum levels of PTHrP, but also the parallel
changes in serum calcium and PTHrP during a course
of therapy. They also demonstrated the presence of
immunoreactive PTHrP in the tumor extract and proved
the bioactivity of the tumor extract producing C-AMP
in osteoblasts. Since that time, a limited number of
patients with hypercalcemic B-cell NHL secondary to
PTHrP have been reported [6,8-15]. Table 2 shows the
clinical and laboratory data of 10 such patients, includ-
ing ours. As shown in Table 2, the hypercalcemia was
severe and life-threatening and immediate therapeutic
modalities such as forced hydration and application of
Figure 4 A CT scan of the patient one year after surgery.
Table 2 Clinical and laboratory data of B-cell NHL patients with hypercalcemia due to PTHrP hypersecretion
Number Age (year) Gender Ca mg/dl PTHrP Pmol/L* LDH Iu/L 1-25(OH)2D3 Pg/ml Outcome Author, Year
1 40 male 18.2 310
(21.8-44.8)
2349 41 died after 3 months Wada et al, 1992
2 64 female 16 151
(13.8-55.3)
1750 Normal Hamihara et al, 1996
3 70 female 26.3 10.3 (<2.5) - <20 Ranganath et al, 1998
4 49 female 16.2 52 (<16) 1795 20.5 died after 2 months Uno et al, 1998
5 73 male 17 1.3 (<0.5) - Normal partial improvement Daroszewski et al, 1999
6 52 male 18.6 8 (<0.8) - - partial improvement Knobel et al, 2001
7 93 female 16.6 5 (<0.6) - - died Ota, 2003
8 69 male 18.8 13 (<1.3) 356 47 died at hospital Schottker et al, 2006
9 50 female 18.3 6.2 (<0.6) 433 17 died at hospital Takasaki et al, 2006
10 85 female 13.3 NA 936 12.8 alive Ghazi et al, 2008
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ken to alleviate the problem.
Serum PTH and 1-25(OH)2D3 were low in most cases
due to suppression of the parathyroid glands and renal
a-hydroxylase secondary to hypercalcemia.
It is also evident that hypercalcemia is a manifestation
of advanced disease and, as with other cases of humoral
hypercalcemia of malignancy (HHM), points to a poor
prognosis. All the patients, except our patient who is
still in remission, died between two to 11 months after
the appearance of hypercalcemia.
Uncontrolled synthesis of 1-25(OH)2D3 as the etiology
of hypercalcemia has also been described in patients
with B-cell NHL [6,16-18].
Conclusions
We conclude that although hypercalcemia is rare in
patients with B-cell NHL, it should be properly diag-
nosed and urgently treated. The evaluation of serum
PTHrP and 1-25(OH)2D3 can be helpful in diagnosis
and management. It should also be noted that presenta-
tion with hypercalcemia has a serious impact on prog-
nosis and survival.
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